



1/14

RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No. 8707  
Hans-Jorg TREICHLER et al. : Attorney Docket No. 2006\_0804A  
Serial No. 10/583,760 : Group Art Unit 1623  
Filed June 21, 2006 : Examiner Ganapathy Krishnan

COBALAMINE DERIVATIVES USEFUL FOR  
DIAGNOSIS AND TREATMENT OF  
ABNORMAL CELLULAR PROLIFERATION : Mail Stop: RCE

**PATENT OFFICE FEE TRANSMITTAL FORM**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached hereto is a check in the amount of \$405.00 to cover Patent Office fees relating to filing the following attached papers:

Request for Continued Examination (RCE) ..... \$405.00

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Hans-Jorg TREICHLER et al.

By William R. Schmidt  
William R. Schmidt, II  
Registration No. 58,327  
Attorney for Applicants

WRS/lc


WENDEROTH, LIND & PONACK, L.L.P.  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
September 24, 2008

[Check No. 87599

2006\_0804A

**REQUEST  
for  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

*Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000,  
provided for continued examination of a utility or plant application  
filed on or after June 8, 1995.  
See the American Inventors Protection Act of 1999 (AIPA).*



Application Number	10/583,760
Filing Date	June 21, 2006
First Named Inventor	Hans-Jorg TREICHLER et al.
Group Art Unit	1623
Examiner Name	Ganapathy Krishnan
Attorney Docket Number	2006_0804A
Confirmation No.	8707

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.


1. Submission required under 37 C.F.R. § 1.114
  - a.  Previously submitted:
    - i.  Please enter and consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
    - ii.  Please consider the arguments in the Appeal Brief or Reply Brief previously filed on
    - iii.  Other
  - b.  Enclosed:
    - i.  Amendment/Reply
    - ii.  Affidavit(s)/Declaration(s)
    - iii.  Information Disclosure Statement (IDS)
    - iv.  Other
2. Miscellaneous
  - a.  Suspension of action on the above-identified application is required under 37 C.F.R. § 1.103(c) for a period of months. (period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(l) required).
  - b.  Other
3. Fees (The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.)
  - a.  The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. .
    - i.  RCE fee required under 37 C.F.R. § 1.17(e)
    - ii.  Extension of time fee (37 C.F.R. § 1.136 and § 1.17)
    - iii.  Other
  - b.  Check in the amount of \$405.00 enclosed

4. CORRESPONDENCE ADDRESS

CUSTOMER NO.

000513

By:

  
William R. Schmidt, II  
Registration No. 58,327

WENDEROTH, LIND & PONACK, L.L.P.  
2033 "K" Street, N.W., Suite 800  
Washington, D.C. 20006-1021  
Phone: (202) 721-8200  
Fax: (202) 721-8250

September 24, 2008

*The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.*